文献速递肝病

MetALD患者饮酒轨迹与主要不良肝脏结局:全国纵向队列研究

Alcohol-Use Trajectories and Major Adverse Liver Outcomes in MetALD: A Nationwide Longitudinal Cohort Study.
PubMed 文献 · Am J Gastroenterol · 2026-09-18

基于韩国全国健康筛查项目85,554例MetALD成人,按三次筛查的饮酒轨迹分为持续饮酒、波动饮酒和持续减少三组。中位随访10.1年,波动饮酒和持续减少组的主要不良肝脏结局风险均低于持续饮酒组,持续减少组关联更强,并伴随部分心脏代谢危险因素的改善。

要点

  • MetALD患者饮酒行为高度动态,纵向饮酒轨迹比单次评估更能反映肝脏风险。
  • 间歇性减少和持续减少饮酒均与主要不良肝脏结局风险降低相关,持续减少关联更强。
  • 持续减少饮酒还伴随空腹血糖受损、高甘油三酯血症和高血压缓解率升高。

核心结论

  • 在MetALD成人中,间歇性减少和持续减少饮酒均与主要不良肝脏结局风险降低相关,持续减少的关联更强。

研究设计与样本

  • 韩国全国健康筛查项目数据,纳入完成三次筛查(2009-2010、2011-2012、2013-2014)的MetALD成人85,554例,按饮酒轨迹分为持续饮酒、波动饮酒和持续减少三组,主要结局为主要不良肝脏结局,以心血管死亡为竞争风险。

主要发现

  • 中位随访10.1年,持续饮酒、波动饮酒和持续减少组分别占32.9%、34.6%和32.4%。
  • 波动饮酒组和持续减少组的主要不良肝脏结局风险低于持续饮酒组,调整后亚分布风险比分别为0.80(95%CI 0.71-0.91)和0.70(95%CI 0.61-0.79),均P<0.001。
  • 与持续饮酒组相比,持续减少组的空腹血糖受损、高甘油三酯血症和高血压缓解率更高。

临床怎么用

  • 对MetALD患者应纵向评估饮酒轨迹,而非仅依据单次饮酒量。
  • 鼓励持续减少饮酒,可能降低主要不良肝脏结局风险并改善部分心脏代谢危险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Alcohol contributes to the progression of steatotic liver disease. However, in individuals with MetALD, the impact of changes in drinking behavior on disease progression remains unclear. We investigated whether longitudinal changes in alcohol consumption were associated with the risk of major adverse liver outcomes (MALO) in people with MetALD. METHODS: Data were obtained from the Korean National Health Screening Program. Adults with MetALD who completed three screening examinations (2009-2010, 2011-2012, and 2013-2014) were included (n = 85,554). Participants were categorized by alcohol consumption trajectories: Group 1 (sustained consumption), Group 2 (fluctuating consumption), and Group 3 (consistent reduction). The primary outcome was MALO, with cardiovascular death treated as a competing risk. Changes in cardiometabolic risk factors from baseline to the last examination were also evaluated. RESULTS: Over a median follow-up of 10.1 years, 32.9%, 34.6%, and 32.4% of participants were classified into Groups 1, 2, and 3, respectively. Groups 2 and 3 had lower MALO risks than Group 1 (adjusted subdistribution hazard ratios (95% confidence intervals), 0.80 (0.71-0.91) and 0.70 (0.61-0.79), respectively; both P <0.001). Compared with Group 1, Group 3 had higher rates of resolution of impaired fasting glucose, hypertriglyceridemia, and hypertension. DISCUSSION: Alcohol use in MetALD was highly dynamic, and hepatic risk was better captured using longitudinal drinking trajectories. Both intermittent and consistent alcohol reduction were associated with lower MALO risk, with a stronger association for consistent reduction. Consistent reduction was also accompanied by favorable changes in selected cardiometabolic risk factors.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Lee JH, Park J, Ahn SH, et al. Alcohol-Use Trajectories and Major Adverse Liver Outcomes in MetALD: A Nationwide Longitudinal Cohort Study. Am J Gastroenterol. 2026. PMID: 42757874. doi:10.14309/ajg.0000000000004212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。